FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113335880> ?p ?o ?g. }

• W2113335880 endingPage "1835" @default.
• W2113335880 startingPage "1829" @default.
• W2113335880 abstract "(18)F-FDG PET/CT allows the direct measurement of metabolic tumor burden in a variety of different malignancies. The aim of this study was to assess whether metabolic tumor volume (MTV) determined by (18)F-FDG PET/CT could be used in the prediction of progression-free and overall survival in multiple myeloma patients.Forty-seven patients (18 women, 29 men; mean age ± SD, 63 ± 11 y) with stage IIIA disease who had undergone whole-body (18)F-FDG PET/CT were retrospectively evaluated. Images underwent a 3-dimensional region-of-interest analysis including all focal lesions with a maximum standardized uptake value > 2.5. The MTV of each lesion was calculated using an automated contouring program based on the standardized uptake value and developed with a threshold of 40% of the maximum standardized uptake value. The total MTV of each patient was defined as the sum of metabolic volume of all focal lesions. Patients were treated and then subjected to a mean follow-up period of 24 mo.In the 47 patients studied, MTV range was 1.3-316.3 mL, with a median of 23.7 mL. A direct, significant correlation was found between MTV and the percentage of diffuse infiltration of bone marrow by plasma cells (r = 0.46, P = 0.006), whereas hemoglobin levels were inversely correlated with MTV (r = -0.56, P = 0.0001). At follow-up, patients who developed progressive disease (n = 18) showed a significantly higher MTV (74.7 ± 19.3 vs. 29.8 ± 5.1 mL, P = 0.009) than patients without progressive disease (n = 29). Furthermore, patients who died of myeloma (n = 9) had a significantly higher MTV (123.2 ± 30.6 vs. 28.9 ± 4.2 mL, P = 0.0001) than survivors (n = 38). No differences in age, plasma cell infiltration, M protein, albumin, β2-microglobulin, performance status, International Staging System score, and presence or absence of a bone marrow transplant were found between groups. The MTV cutoff level was determined by receiver-operating-characteristic curve analysis, and the best discriminative value found for predicting progression-free and overall survival was 42.2 and 77.6 mL, respectively. By Kaplan-Meier analysis and log-rank testing, progression-free and overall survival at follow-up were significantly better in patients showing an MTV lower than the cutoff than in those having an MTV higher than the cutoff (χ(2) = 3.9, P = 0.04, and χ(2) = 56.3, P < 0.0001, respectively).The direct measurement of tumor burden obtained by calculating MTV on (18)F-FDG PET/CT images may be used in the prediction of progression-free and overall survival in myeloma patients." @default.
• W2113335880 created "2016-06-24" @default.
• W2113335880 creator A5001338039 @default.
• W2113335880 creator A5016720117 @default.
• W2113335880 creator A5044760713 @default.
• W2113335880 creator A5045672021 @default.
• W2113335880 creator A5049072084 @default.
• W2113335880 creator A5057084037 @default.
• W2113335880 creator A5070587577 @default.
• W2113335880 creator A5074115401 @default.
• W2113335880 creator A5078017458 @default.
• W2113335880 date "2012-10-15" @default.
• W2113335880 modified "2023-10-14" @default.
• W2113335880 title "Metabolic Tumor Volume Assessed by ¹⁸F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma" @default.
• W2113335880 cites W1594485137 @default.
• W2113335880 cites W1967121367 @default.
• W2113335880 cites W1968456152 @default.
• W2113335880 cites W1969552142 @default.
• W2113335880 cites W1978459845 @default.
• W2113335880 cites W1984259729 @default.
• W2113335880 cites W1985194686 @default.
• W2113335880 cites W1986119528 @default.
• W2113335880 cites W2002052629 @default.
• W2113335880 cites W2006382315 @default.
• W2113335880 cites W2011474526 @default.
• W2113335880 cites W2020003931 @default.
• W2113335880 cites W2050281367 @default.
• W2113335880 cites W2065996714 @default.
• W2113335880 cites W2073370692 @default.
• W2113335880 cites W2074831264 @default.
• W2113335880 cites W2077130506 @default.
• W2113335880 cites W2085758206 @default.
• W2113335880 cites W2086380649 @default.
• W2113335880 cites W2095255742 @default.
• W2113335880 cites W2100285775 @default.
• W2113335880 cites W2103584561 @default.
• W2113335880 cites W2104182459 @default.
• W2113335880 cites W2105656190 @default.
• W2113335880 cites W2107156713 @default.
• W2113335880 cites W2139789239 @default.
• W2113335880 cites W2144129115 @default.
• W2113335880 cites W2149634568 @default.
• W2113335880 cites W2153830371 @default.
• W2113335880 cites W2159705543 @default.
• W2113335880 cites W2160994783 @default.
• W2113335880 cites W2163480869 @default.
• W2113335880 cites W4321317560 @default.
• W2113335880 doi "https://doi.org/10.2967/jnumed.112.106500" @default.
• W2113335880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23071351" @default.
• W2113335880 hasPublicationYear "2012" @default.
• W2113335880 type Work @default.
• W2113335880 sameAs 2113335880 @default.
• W2113335880 citedByCount "151" @default.
• W2113335880 countsByYear W21133358802013 @default.
• W2113335880 countsByYear W21133358802014 @default.
• W2113335880 countsByYear W21133358802015 @default.
• W2113335880 countsByYear W21133358802016 @default.
• W2113335880 countsByYear W21133358802017 @default.
• W2113335880 countsByYear W21133358802018 @default.
• W2113335880 countsByYear W21133358802019 @default.
• W2113335880 countsByYear W21133358802020 @default.
• W2113335880 countsByYear W21133358802021 @default.
• W2113335880 countsByYear W21133358802022 @default.
• W2113335880 countsByYear W21133358802023 @default.
• W2113335880 crossrefType "journal-article" @default.
• W2113335880 hasAuthorship W2113335880A5001338039 @default.
• W2113335880 hasAuthorship W2113335880A5016720117 @default.
• W2113335880 hasAuthorship W2113335880A5044760713 @default.
• W2113335880 hasAuthorship W2113335880A5045672021 @default.
• W2113335880 hasAuthorship W2113335880A5049072084 @default.
• W2113335880 hasAuthorship W2113335880A5057084037 @default.
• W2113335880 hasAuthorship W2113335880A5070587577 @default.
• W2113335880 hasAuthorship W2113335880A5074115401 @default.
• W2113335880 hasAuthorship W2113335880A5078017458 @default.
• W2113335880 hasBestOaLocation W21133358801 @default.
• W2113335880 hasConcept C126322002 @default.
• W2113335880 hasConcept C126838900 @default.
• W2113335880 hasConcept C127413603 @default.
• W2113335880 hasConcept C199374082 @default.
• W2113335880 hasConcept C199639397 @default.
• W2113335880 hasConcept C2775842073 @default.
• W2113335880 hasConcept C2776364478 @default.
• W2113335880 hasConcept C2779104521 @default.
• W2113335880 hasConcept C2780007613 @default.
• W2113335880 hasConcept C2989005 @default.
• W2113335880 hasConcept C71924100 @default.
• W2113335880 hasConceptScore W2113335880C126322002 @default.
• W2113335880 hasConceptScore W2113335880C126838900 @default.
• W2113335880 hasConceptScore W2113335880C127413603 @default.
• W2113335880 hasConceptScore W2113335880C199374082 @default.
• W2113335880 hasConceptScore W2113335880C199639397 @default.
• W2113335880 hasConceptScore W2113335880C2775842073 @default.
• W2113335880 hasConceptScore W2113335880C2776364478 @default.
• W2113335880 hasConceptScore W2113335880C2779104521 @default.
• W2113335880 hasConceptScore W2113335880C2780007613 @default.
• W2113335880 hasConceptScore W2113335880C2989005 @default.
• W2113335880 hasConceptScore W2113335880C71924100 @default.
• W2113335880 hasIssue "12" @default.

• next